Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)
India · Delayed Price · Currency is INR 1,801.00
-15.60 (-0.86%)
Oct 1, 2026, 3:15 PM IST
NSE:SUNPHARMA Stock Forecast
Stock Price Forecast
According to 33 analysts polled by S&P Global, NSE:SUNPHARMA stock has a consensus rating of "Buy" and an average price target of ₹2,176. The average 1-year stock price forecast is 20.80% higher than the current stock price, while the lowest is ₹1,830 (+1.61%) and the highest is ₹2,400 (+33.26%).
Price Target: ₹2,176 (+20.80%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for NSE:SUNPHARMA stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 22 | 20 | 20 | 20 | 19 | 18 |
| Buy | 7 | 10 | 10 | 10 | 10 | 10 |
| Hold | 0 | 1 | 1 | 1 | 1 | 1 |
| Sell | 2 | 2 | 2 | 2 | 3 | 3 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 32 | 34 | 34 | 34 | 34 | 33 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst Geojit Research No rating | Geojit Research | Buy Maintains ₹2,070 | Buy | Maintains | ₹2,070 | +14.94% | Sep 22, 2026 |
Financial Forecast
Revenue This Year
651.12B
from 584.62B
Increased by 11.37%
Revenue Next Year
729.51B
from 651.12B
Increased by 12.04%
EPS This Year
54.67
from 52.01
Increased by 5.11%
EPS Next Year
64.54
from 54.67
Increased by 18.05%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is INR.